“CMD’s F3Q18 revenue missed and EPS met consensus. Overall organic revenue growth slowed to 7.6% CC in F3Q18 from 10.0% CC in F2Q18. The revenue miss was driven by Endoscopy, which slowed from F2Q18 despite facing an easier comp. Water Purification growth improved from F2Q18 and and beat our estimate while Healthcare Disposables growth slowed slightly from F2Q18 and met our estimate. Adjusted gross margin was up 40 bps Y/Y due mainly to product mix and adjusted operating margin was down 50 bps Y/Y. We maintain our Hold given the slowing Endoscopy growth and CMD’s valuation (despite today’s decline, CMD still trades at a 39.7x vs. its small/mid-cap GARP peers median of 33.3x).”
According to TipRanks.com, Matson is a 5-star analyst with an average return of 10.2% and a 62.6% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Cantel Medical Corp has an analyst consensus of Hold.
Cantel Medical Corp’s market cap is currently $5.41B and has a P/E ratio of 60.08. The company has a Price to Book ratio of 9.23.
Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cantel Medical Corp. engages in the provision, development, and manufacture of infection prevention products and services in the healthcare market. It operates through the following business segments: Endoscopy; Water Purification and Filtration; Healthcare Disposables; Dialysis; and Other.